BDBM62525 (5Z)-3-ethyl-5-(phenylazanylmethylidene)-2-sulfanylidene-1,3-oxazolidin-4-one::(5Z)-5-(anilinomethylene)-3-ethyl-2-thioxo-oxazolidin-4-one::(5Z)-5-(anilinomethylidene)-3-ethyl-2-sulfanylidene-1,3-oxazolidin-4-one::(5Z)-5-(anilinomethylidene)-3-ethyl-2-sulfanylidene-4-oxazolidinone::3-Ethyl-5-[1-phenylamino-meth-(Z)-ylidene]-2-thioxo-oxazolidin-4-one::MLS000070621::SMR000009004::cid_5756988

SMILES O=C(c1cnc2c(c1)OCCN2c1ccn2c(=O)n(-c3ccccn3)nc2c1)N1CCCCC1

InChI Key InChIKey=MIWJULPPZGBHHR-UHFFFAOYSA-N

Data  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 62525   

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Kyorin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 62525BDBM62525(US12577217, Example 1-35)
Affinity DataIC50: 10nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent